A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer

Lee S. Rosen, Jonathan W. Goldman, Alain P. Algazi, P. Kellie Turner, Brian Moser, Tianle Hu, Xuejing Aimee Wang, Jay Tuttle, Volker Wacheck, James E. Wooldridge, Michaela Banck

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences